The global piperazine market size was valued at US$ 3.3 Bn in 2024 and is projected to reach US$ 5.5 Bn by 2035, growing at a CAGR of 4.7% during 2025–2035.

The tribunal held that brought-forward losses and unabsorbed depreciation remain in the books until fully absorbed and must be allowed as reduction under Section 115JB. The ruling rejects the ...